By the analysis of a previously published gene expression profile of a data set of BCC lines (GEO accession number: GSE6569) [23], we observed that CDH3 expression correlates with the sensitivity/resistance of breast cancer cells to dasatinib [24]. This evidence concerns the gene CDH3 and skin basal cell carcinoma.